Posted on 14/05/2009 in Pharmaceutical Company Financials ProStrakan achieved a 20 per cent sales increase of Adcal-D3 between January 1st and April 30th compared to the same period in 2008.
Used for patients with osteoporosis and those requiring malnutrition supplements, the product held a 45.2 per cent share of the calcium and vitamin D supplement market during March.
Available only in the UK, it managed to achieve these results despite the Department of Health's Pharmaceutical Price Regulation Scheme, which saw a 3.9 per cent price decrease in February.
In today's (May 14th) interim management statement, the firm also revealed total product revenues for the first four months of the year had increased by 40 per cent compared to 2008.
Dr Wilson Totten, chief executive of the business, noted the company had made a "strong start" to the year.
"The strength of our performance in the first four months of 2009 reinforces our confidence in achieving our stated target of reaching breakeven in the closing months of 2009," he said.
In March, ProStraken received marketing authorisation from both the French and Spanish regulatory authorities for the breakthrough cancer pain treatment Abstral.Other news stories from 14/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
